Hemostatic Factors and the Metabolic Syndrome

Author(s): Michael S. Kostapanos, Matilda Florentin, Moses S. Elisaf, Dimitri P. Mikhailidis

Journal Name: Current Vascular Pharmacology

Volume 11 , Issue 6 , 2013

Become EABM
Become Reviewer
Call for Editor


Metabolic syndrome (MetS) is associated with increased risk of both atherothrombotic cardiovascular events and venous thromboembolism. The pro-thrombotic potential of MetS, may explain this association. In this review we discuss the relationship of MetS with hemostasis focusing on endothelial function, platelet activity, coagulation, fibrinolysis and hemorheologic markers. Endothelial-dependent vasodilatation is impaired in MetS. This is mostly mediated by a reduced expression of vasodilators (nitric oxide and prostacyclin) with a concomitant increase of vasoconstrictors (endothelin- 1, angiotensin II and thromboxane A2). Platelet activity is enhanced in MetS. A cross-talk between activated endothelium and platelets results in a pro-thrombotic vicious cycle. Enhanced coagulation together with impaired fibrinolysis is also present in MetS. This is mirrored by high fibrinogen and plasminogen activator inhibitor-1 levels. Endothelial dysfunction, expressed by high von Willebrand factor and tissue plasminogen factor levels, also contributes to this abnormality. Whole blood and plasma viscosity is increased in MetS.

Lifestyle intervention can improve the MetS-related pro-thrombotic state. These measures include weight reduction and improved composition of the diet. A Mediterranean-style diet rich in olive oil, as a source of monounsaturated fat, and low saturated fat consumption may also be beneficial.

Keywords: Metabolic syndrome, hemostasis, endothelium, platelet, coagulation, fibrinolysis, viscosity.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2013
Page: [880 - 905]
Pages: 26
DOI: 10.2174/15701611113116660171
Price: $65

Article Metrics

PDF: 40